Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
A clinical trial is underway to evaluate the efficacy of intismeran autogene combined with pembrolizumab in NSCLC patients.
Asset / Drug
Drug and asset intelligence for Intismeran with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.